Tumors

MDA-7 activates immune system, has antiangiogenic properties

Published in Gene Therapy Weekly, January 23rd, 2003

Introgen Therapeutics, Inc., (INGN) announced that the MDA-7 protein, encoded by the tumor suppressor gene employed in INGN 241, has potent anti-angiogenic activity, an important mechanism for inhibiting the growth of tumors.

This discovery resulted in the reclassification of mda-7 as interleukin-24, or IL-24. Interleukins are a class of proteins that regulate the immune system and have been shown to be integral in controlling cancer. These data were described in oral presentations at the 11th International Conference on Gene Therapy of Cancer, recently held in San Diego, California.

One presentation described data that mda-7 is a multifunctional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry